Beranda › Mieloma Multipel › Rhode Island
Uji klinis Mieloma Multipel di Rhode Island
6 studi untuk Mieloma Multipel mencari peserta di lokasi di Rhode Island.
Kota di Rhode Island
Teks studi resmi (Bahasa Inggris)
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Rhode Island Hospital, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05552222MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Rodhe Island Hospital, Providence
- The Miriam Hospital, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Smilow Cancer Hospital Care Center - Westerly, Westerly
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04566328Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Smilow Cancer Hospital Care Center - Westerly, Westerly
Menerima pesertaFase 3
Semua usia · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT05561387A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT06679101IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Rhode Island Hospital, Providence
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2025 · NCT06119685Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.